Similar articles

• [Thrombolytic therapy for myocardial infarction in oral anticoagulation].

  Pizzulli L, Lüderitz B. Pizzulli L, et al. Dtsch Med Wochenschr. 1996 Mar 29;121(13):424. Dtsch Med Wochenschr. 1996. PMID: 8681737 German. No abstract available.
• [Experience with the thrombolytic therapy of myocardial infarct].

  Gospodarenko AL, Ardashev VN, Tiurin VP, Chernetsov VA, Iakovlev VB, Vrublevskiĭ OIu, Makarenko AS, Sokolianskiĭ NV, Chernov SA, Kucherov VV, Davrent'eva TA. Gospodarenko AL, et al. Voen Med Zh. 1997 Nov;318(11):40-5. Voen Med Zh. 1997. PMID: 9461835 Russian. No abstract available.
• Evaluation and comparison of the adverse effects of streptokinase and alteplase.

  Tisdale JE, Colucci RD, Ujhelyi MR, Kluger J, Fieldman A, Chow MS. Tisdale JE, et al. Pharmacotherapy. 1992;12(6):440-4. Pharmacotherapy. 1992. PMID: 1492007 Clinical Trial.
• Cholesterol embolization syndrome following thrombolytic therapy with streptokinase and tissue plasminogen activator.

  Ben-Chitrit S, Korzets Z, Hershkovitz R, Bernheim J, Schneider M, Bernheim J. Ben-Chitrit S, et al. Nephrol Dial Transplant. 1994;9(4):428-30. Nephrol Dial Transplant. 1994. PMID: 8084460 Review. No abstract available.
• Anticoagulation.

  Chong BH. Chong BH. Aust Fam Physician. 1996 Jan;25(1):74-8. Aust Fam Physician. 1996. PMID: 8607780 Review.